94 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
strategy and filing preparations.
Primary Deal Terms
In consideration for an investment of $2,700,000 and the payment of all costs related to obtaining
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
is the Chief Technology Officer of MainPointe. The RepliCel and MainPointe teams actively collaborate on the US regulatory strategy and filing
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
compensation strategy is to offer medium-term and long-term compensation components to ensure that the Company has in place programs to attract, retain … and capabilities demonstrated by the executive officers.
Options are an important part of the Company's long-term incentive strategy for its officers
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
9 Aug 23
Statement of Executive Compensation
7:41pm
.
Goals and Objectives
The overall objective of the Company’s compensation strategy is to offer medium-term and long-term compensation components … part of the Company’s long-term incentive strategy for its officers, permitting them to participate in any appreciation of the market value
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
of MainPointe. The RepliCel and MainPointe teams are actively collaborating on the US regulatory strategy and filing preparations.
Primary Deal Terms
6-K
EX-99.2
3ukk2d6jlkupze24
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
w12f64e
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
3eqn6 j5zp
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
vchwcd ho8o
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
bufvxey0
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
wdmhud4 517ao1z
7 Jul 22
Statement of Executive Compensation
1:43pm
6-K
EX-99.1
c65vv3s78b2ou4av
30 Jun 22
Statement of Executive Compensation
11:16am
6-K
EX-99.1
de8g4g qltrl0zmq
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.1
ius5q5asb2v37 9td
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
lo6 znsezjreko
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
prh709jqsihwdeh5k1k
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.1
3jbj5tu n759c
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.1
a54t2erp7 2io7o
18 Aug 21
Current report (foreign)
12:20pm